Neoadjuvant Therapy in Breast Cancer Patients and Assessment of Response in Relation to Regimen Used and Prognostic Factors
Dalia Mohamed Magdy Hamza Elsheikh;
Abstract
Abstract
Background: The pathological complete response of neoadjuvant (preoperative) therapy in non metastatic breast cancer patients has been correlated with outcome and prognosis in terms of local and distant relapse. Response rates vary according to clinical and pathological prognostic factors of patients especially molecular subtypes. This study was performed to assess response in terms of pathological response rates in relation to regimen used and prognostic factors.
Methods: This study analyzed 99 female patients with non metastatic breast cancer who received neoadjuvant chemotherapy ± targeted therapy during the period of April 2007 to March 2014. Patients were treated at the university hospital of Saarland in Homburg,Germany. Records were reviewed to assess the regimens given, the toxicity and correlation of response to regimen and prognostic factors was done. Response evaluation was done according to Sinn et al., and was defined as absence of invasive and in situ disease in breast and axilla. Relapse was also correlated to regimen and prognostic factors.
Results: Out of 99 patients, 29 (29.3%) patients achieved pCR. Patients receiving regimens incorporating Anti HER2 agents achieved pCR in 52.6%. Age grouping below versus equal to or above 60 years of age was found to be statistically significant in correlation with pCR (P value 0.05). Similarly pCR was observed in 33.3% of T1/T2 tumors versus 11.5% of T3/T4 tumors which showed statistical significance (P value 0.033). Fourty two percent of tumors with negative Estrogen receptor status achieved complete response, versus 18% of ER positive tumors which was found to be of statistical significance (P value 0.009). Similarly 42.6% of tumors with negative Progesterone receptors showed pCR versus only 10% of PR positive tumors which also showed high significance (P value 0.000).HER2 receptor status also showed to be of statistical significance when correlated with pathological complete response (P value 0.011). HER2 positive tumors showed complete pathological response in 55% versus 23.5% of HER2 negative tumors.
Background: The pathological complete response of neoadjuvant (preoperative) therapy in non metastatic breast cancer patients has been correlated with outcome and prognosis in terms of local and distant relapse. Response rates vary according to clinical and pathological prognostic factors of patients especially molecular subtypes. This study was performed to assess response in terms of pathological response rates in relation to regimen used and prognostic factors.
Methods: This study analyzed 99 female patients with non metastatic breast cancer who received neoadjuvant chemotherapy ± targeted therapy during the period of April 2007 to March 2014. Patients were treated at the university hospital of Saarland in Homburg,Germany. Records were reviewed to assess the regimens given, the toxicity and correlation of response to regimen and prognostic factors was done. Response evaluation was done according to Sinn et al., and was defined as absence of invasive and in situ disease in breast and axilla. Relapse was also correlated to regimen and prognostic factors.
Results: Out of 99 patients, 29 (29.3%) patients achieved pCR. Patients receiving regimens incorporating Anti HER2 agents achieved pCR in 52.6%. Age grouping below versus equal to or above 60 years of age was found to be statistically significant in correlation with pCR (P value 0.05). Similarly pCR was observed in 33.3% of T1/T2 tumors versus 11.5% of T3/T4 tumors which showed statistical significance (P value 0.033). Fourty two percent of tumors with negative Estrogen receptor status achieved complete response, versus 18% of ER positive tumors which was found to be of statistical significance (P value 0.009). Similarly 42.6% of tumors with negative Progesterone receptors showed pCR versus only 10% of PR positive tumors which also showed high significance (P value 0.000).HER2 receptor status also showed to be of statistical significance when correlated with pathological complete response (P value 0.011). HER2 positive tumors showed complete pathological response in 55% versus 23.5% of HER2 negative tumors.
Other data
| Title | Neoadjuvant Therapy in Breast Cancer Patients and Assessment of Response in Relation to Regimen Used and Prognostic Factors | Authors | Dalia Mohamed Magdy Hamza Elsheikh | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.